title: Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.
abstract: BACKGROUND
  Trastuzumab (T) combined with chemotherapy has been recently shown to improve outcome in HER2-positive breast cancer (BC). The aim of this study was to evaluate the toxic effects of concurrent radiation therapy (RT) and T administration in the adjuvant setting.
  
  
  METHODS
  Data of 146 patients with stages II-III HER2-positive BC were recorded. Median age was 46 years. In all, 32 (23%) and 114 (77%) patients received a weekly and a 3-week T schedule, respectively. A median dose of 50 Gy was delivered after surgery. Internal mammary chain (IMC) was irradiated in 103 (71%) patients.
  
  
  RESULTS
  Grade >2 dermatitis and esophagitis were noted in 51% and 12%, respectively. According to the Common Toxicity Criteria v3.0 scale and HERA (HERceptin Adjuvant) trial criteria, respectively, 10% and 6% of the patients had a grade >/=2 of left ventricular ejection fraction (LVEF) decrease after RT. Multivariate analyses revealed two independent prognostic factors: weekly T administration (for LVEF decrease) and menopausal status (for dermatitis). Higher level of T cumulative dose (>1600 mg) was only borderline of statistical significance for acute esophagitis toxicity.
  
  
  CONCLUSIONS
  We showed that weekly concurrent T and RT are feasible in daily clinical practice with, however, a decrease of LVEF. Cardiac volume sparing and patient selections for IMC irradiation are highly recommended. Longer follow-up is warranted to evaluate late toxic effects.
authors.affiliation: Department of Radiation Oncology, CLCC Oscar Lambret Anti-Cancer Center, University of Lille II, Lille, France. y-belkacemi@o-lambret.fr
authors.forename: Y
authors.initials: Y
authors.lastname: Belkacémi
authors.forename: J
authors.initials: J
authors.lastname: Gligorov
authors.forename: M
authors.initials: M
authors.lastname: Ozsahin
authors.forename: H
authors.initials: H
authors.lastname: Marsiglia
authors.forename: B
authors.initials: B
authors.lastname: De Lafontan
authors.forename: H
authors.initials: H
authors.lastname: Laharie-Mineur
authors.forename: L
authors.initials: L
authors.lastname: Aimard
authors.forename: E-C
authors.initials: EC
authors.lastname: Antoine
authors.forename: B
authors.initials: B
authors.lastname: Cutuli
authors.forename: M
authors.initials: M
authors.lastname: Namer
authors.forename: D
authors.initials: D
authors.lastname: Azria
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy; D003131:Combined Modality Therapy / Q000009:adverse effects; D003872:Dermatitis / Q000209:etiology; D004941:Esophagitis / Q000209:etiology; D005260:Female; D005602:France; D006801:Humans; D008408:Mastectomy; D008875:Middle Aged; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab